Introduction
Mammals are diploid for all autosomal genes and the majority of genes are assumed to be expressed from both alleles within the cell. However, not all genes are biallelically expressed. A subset of genes are expressed from only one allele in a parent-specific manner. Such genes are subject to the phenomenon of gametic imprinting. Gametic imprinting, also known as genomic or parental imprinting, is defined as a gametic modification which can induce parental-specific effects.
The study of gametic imprinting in humans and mice has been complementary through a number of different observations and experimental approaches. From the manipulation of early mouse embryos to the observation of parental effects in human genetic disease, work on both species has contributed to an understanding of imprinting and its clinical effects. In this review I shall describe the data that led to the identification of imprinting in both mice and humans and discuss how the study of imprinted genes in both species continues to provide insights into the molecular basis of imprinting and its role in disease and cancer.
Non-equivalence of parental genomes in mice and humans
The manipulation of mouse embryos in vitro to produce diploid embryos with only maternal or paternal genomes provided the first clear evidence for the phenomenon of gametic imprinting. Initially the production of parthenogenetic embryos, in a number of vertebrate species, indicated that normal development could occur with only a maternally derived diploid genome. However, the demonstration that mammalian parthenogenotes are not viable suggested this was not true for all species (Kaufman et al. 1977) . A number of reasons were postulated for this failure to complete development: homozygosity for recessive lethal alleles, lack of an extragenetic contribution from the fertilizing sperm or non-equivalence of the parental genomes (Graham 1974) .
Experiments to distinguish between these alternatives used nuclear transplantation to create embryos with different parental constitutions (embryos which develop from two maternal nuclei after activation by the male gamete are termed gynogenotes and those which develop from two paternal haploid nuclei are androgenotes; Fig. 1 ). Neither parthenogenotes nor diploid biparental gynogenetic and androgenetic embryos develop to term (McGrath & Solter 1984a , Surani et al. 1984 . Both androgenetic and gynogenetic embryos can develop to the blastocyst stage, but die shortly after implantation. The fact that these embryos were derived from inbred mice rules out the possibility that the lethality was due to homozygosity for recessive mutations. The demonstration that gynogenetic embryos develop to the same stage as parthenogenotes suggested that it was not a cytoplasmic contribution from sperm which led to the developmental failure (Surani & Barton 1983) . Nuclear transplantation experiments with pronuclei derived from T hp mice (a maternal effect mutation on chromosome 17 (Johnson 1974)) also confirmed that the phenotypic effect was nuclear and not cytoplasmic. A T hp /+ pronucleus injected into an anucleate egg derived from wild-type mice did not produce viable offspring, whereas the reciprocal nuclear transfer was viable (McGrath & Solter 1984b) .
The conclusion from these experiments was that the parental genomes are not equivalent in the information they contribute to the embryo. From this it follows that one or both parental genomes must be marked in some way to modify their genetic information (McGrath & Solter 1984a , Surani et al. 1984 . This mark which confers parental 'memory' has become known as the imprint. The imprint has been shown to remain on the parental chromosomes after cell division: transplantation of nuclei from haploid early preimplantation embryos (two to eight cells) back into fertilized eggs from which one pronucleus had been removed develop to term, only if the donor nucleus was derived from the opposite sex of the remaining pronucleus, demonstrated that the imprinting mark is heritable (Surani et al. 1986) .
Gynogenotes and androgenotes are generally much smaller than normal littermates (Surani & Barton 1983) . In addition, the parental genomes do not contribute equally to the tissues of the developing embryo, apparently fulfilling complementary functions. Androgenotes have relatively poorly developed embryonic tissue but welldeveloped extraembryonic membranes and trophoblast (Barton et al. 1984) , gynogenotes have a relatively normal (though small) embryo, while the extraembryonic tissues are not well developed (Surani & Barton 1983 , Surani et al. 1984 , Barton et al. 1985 . The paternal genome thus appears more important for proliferation of the extraembryonic tissues and the maternal genome for postimplantation embryonic development. Construction of chimaeras between androgenetic and parthenogenetic cells reinforced this conclusion, since androgenetic cells preferentially contribute to the extraembryonic tissues and gynogenetic cells to the embryo (Surani et al. 1987 , Mann et al. 1990 ). More recent analysis of parthenogenetic, androgenetic and gynogenetic cells aggregated with normal embryos to form chimaeras has shown that such cells also contribute unequally to the organs within the embryo itself (Barton et al. 1991 , Hardy & Handyside 1996 .
Naturally occurring equivalents of androgenetic and parthenogenetic mouse embryos exist in humans. Hydatidiform moles, like androgenotes, are diploid for the paternal genome, and arise through fertilization of an anucleate oocyte (Jacobs et al. 1980) . These moles are similar to androgenetic embryos in that they show hypertrophy of extraembryonic structures and lack embryonic tissue. Ovarian teratomas are benign embryonal tumours which develop with only a diploid maternal genome and are thus parthenogenetic (Surti et al. 1990 ). Similar to mouse parthenogenotes, ovarian teratomas have embryonic tissues but do not contain extraembryonic structures.
A minor portion of the mammalian genome is imprinted
More subtle analyses of the regions of the genome which contribute to parent-dependent phenotypic effects have been made possible by the use of translocation strains of mice that show a high rate of non-disjunction. Offspring derived from these mice often show uniparental disomy (UPD) for specific chromosomes, they are diploid but a region of the genome is of maternal or paternal origin only Construction of diploid embryos with genomes derived from a single sex. In a fertilized egg, the male and female pronuclei can be removed before they fuse, and a diploid egg recreated by injection of another pronucleus. The development of these diploid eggs can then be followed in vitro by culturing, or in vivo by transplantation to pseudopregnant mice. Parthenogenetic embryos can be created by the chemical activation of an unfertilized egg. (Cattanach & Kirk 1985, Fig. 2) . Selective breeding in mice has allowed the analysis of most of the genome (Cattanach & Beechey 1990) , and naturally occurring cases of UPD have allowed similar, though less definitive, analyses in humans (Ledbetter & Engel 1995) .
The phenotypes of UPD mice range from embryonic lethal to postnatal growth effects (Cattanach & Beechey 1990) . For some chromosomal regions, the opposite, complementing phenotypes are produced dependent on the parent of origin of the UPD, reminiscent of the results from androgenotes and parthenogenotes. For example, for proximal chromosome 11, paternal UPD results in growth enhancement and maternal UPD in a growth decrease, suggestive of a paternally expressed growth enhancer or a maternally expressed negative regulator of growth mapping to this region.
Such studies have shown that the effects observed in experiments with parthenogenetic, gynogenetic and androgenetic embryos are attributable to a relatively small subset of the genome (reviewed in Cattanach & Beechey 1990). Large chromosomal regions have been identified which appear to show no imprinting effects (Cattanach et al. 1993 , Beechey & Cattanach 1996 . In total, ten regions of the mouse genome have been identified which display parental-specific effects (Beechey & Cattanach 1996) , and it is now clear that imprinted genes are clustered within the genome (see later). Whether such studies can truly identify all regions containing imprinted genes is not yet clear since imprinted genes associated with mild phenotypes, or those modified by genetic background, may not be identified in this type of screen. The use of translocations and non-disjunction to create mice with UPD for specific chromosomal regions. In the example, chromosomes 2 and 11 are shown, with a translocation (2; 11). A marker gene (illustrated by plus and minus) can be used to identify the progeny with UPD. It should be noted that only those progeny which show UPD are illustrated in the example.
PATERNAL DISOMY
In humans, UPD has been associated with a number of diseases which have been used to construct a similar imprinting map (Ledbetter & Engel 1995) . Such a map, though not as detailed as the mouse map, again demonstrates that not all chromosomes show parental origin effects, and that the identified chromosomes have homology of synteny with the regions identified in the mouse. Interestingly, three out of the four regions defined by Ledbetter & Engel (1995) as showing certain imprinting effects are associated with a growth abnormality phenotype.
In conclusion, the nuclear transplantation and genetic experiments demonstrate the non-equivalence of parental genomes, and indicate that only a subset of genes within the genome function differently depending on their parental origin.
Identification and study of imprinted genes
The first imprinted gene to be identified was the mouse insulin-like growth factor type 2 receptor (Igf2r), which was isolated by positional cloning as the gene responsible for the T maternal effect (Tme) phenotype, a naturally occurring mouse mutant known to display parental origin effects (Barlow et al. 1991 , Lau et al. 1994 , Wang et al. 1994 . Igf2r is expressed exclusively from the maternal allele. The next gene to be identified, Igf2, was shown to be imprinted by examining the phenotypes of progeny from reciprocal crosses heterozygous for a targeted mutation (DeChiara et al. 1991) . These experiments demonstrated that the mutant phenotype was observed only when the mutant gene was inherited from the father: Igf2 is expressed exclusively from the paternal allele in most embryonic tissues.
Since these initial findings, imprinted genes have been identified by a number of means in both mouse and human. Using the available information from imprinting maps, imprinted genes have been identified both by testing genes which map to these regions for imprinting effects, for example the mouse H19 gene (Bartolomei et al. 1991) , and by extending gene maps within imprinted regions, for example the human IPW gene (Wevrick et al. 1994) . In addition, systematic screens, using different approaches, have been made to identify imprinted genes, with varying degrees of success; for example, searching for methylation differences in the genome (Hatada et al. 1993) , and differential expression of genes (Kaneko-Ishino et al. 1995) or proteins (Bowden et al. 1996 ) from normal and parthenogenetic embryos.
Twenty-one imprinted genes have now been reported, and imprinting seems to be well conserved between mice and humans (Table 1) . Of the ten genes tested in both species, three, WT1, IGF2R and GNAS1, show differences in the pattern of allelic expression between mice and humans. The total number of imprinted genes present in the genomes of mouse and human is difficult to estimate but, based on mouse mutants (either natural or engineered knockouts) which display parental effects, 100-200 have been estimated (Barlow 1995) . Most imprinted genes identified in the mouse map to regions previously identified as involved in imprinting (the exceptions being Ins1 and Grf1). In humans also, imprinted genes identified so far map to regions showing UPD phenotypes. However, since many searches have concentrated in the small number of regions associated with UPD effects, genome wide screens may yet find more imprinted genes mapping outside these regions.
Imprinted genes encode a surprisingly wide range of products (Table 1) , including non-coding RNAs, growth factors and transcription factors. The functions of these genes can be analyzed by gene targeting in mice and the identification of genes causing imprinted disease phenotypes in humans. Five imprinted genes have so far been analyzed by knockout in mice (Table 2) , and they all affect embryonic development. Indeed, it is striking that four out of these five show a growth-effect phenotype (Barlow 1995) . In humans, a number of diseases involving imprinting which also have growth defect phenotypes are known (see later). Several authors have suggested that imprinting may have evolved to regulate embryonic and placental growth (Moore & Haig 1991 , Varmuza & Mann 1994 . However, it is difficult to draw conclusions from the few genes analyzed, especially in light of the fact that Igf2 and two genes which regulate its expression constitute three of the five studied.
The identification and analysis of imprinted gene function enable us to ask if individual genes are responsible for the phenotypes of UPD cases. Paternal duplication of distal chromosome 7 in the mouse is an early embryonic lethal (Cattanach & Beechey 1990 , McLaughlin et al. 1996 , and three imprinted genes which have been analyzed by gene targeting map to this region. The Mash 2 mutant phenotype may account for the observed UPD phenotype (Guillemot et al. 1994) , since these appear to be identical. The Igf2r / mice and the Tme mutant mice have a very similar phenotype, strongly arguing that this gene is responsible for the phenotypes observed for paternal UPD or maternal deletion of proximal chromosome 17 (Barlow et al. 1991 , Wang et al. 1994 .
As more imprinted genes have been identified, it has become increasingly clear that they are clustered within the genome, which suggests that there may be a functional basis for grouping imprinted genes. In mice, deletion of the H19 gene or its enhancers results in disruption of imprinting of two upstream genes, Igf2 and Ins2 (Leighton et al. 1995a,b) . In humans, a postulated imprinting centre (IC) has been suggested to control the imprinting of a number of genes within the Prader-Willi syndrome region (Sutcliffe et al. 1994 , Buiting et al. 1995 ) (see later). In addition to these effects on gene expression, more global effects on chromosome function appear to occur within imprinted domains which lend support to the argument that there may be a functional basis for grouping imprinted genes. Such domains show parental differences in replication timing (Kitsberg et al. 1993 ) and meiotic recombination (Paldi et al. 1995) , and imprinted regions may also show homologous association at certain stages of the cell cycle (LaSalle & Lalande 1996) . How these domain effects may relate causally to the mechanism of imprinting is not clear at present. However, taken together, these data would strongly argue that imprinted genes are organized into functional domains within both the mouse and human genomes.
The clustering of imprinted genes and the existence of co-ordinate regulation may make it difficult to interpret the UPD phenotypes. It is not until more imprinted genes have been identified and their individual phenotypic effects analyzed that we can begin to understand the complex phenotypes seen in both mouse mutants and human disease. We may also gain insight into why imprinting involves such a seemingly diverse set of genes, and whether they conform to some category of genes involved in a developmental or growth-regulatory role.
Imprinted genes and human genetic disease
There are a number of human genetic diseases which have imprinting effects (reviewed in Clark 1990 , Hall 1990 and, with the identification of imprinted genes, many of the underlying molecular mechanisms of these diseases are now beginning to be understood. The first indication that imprinting may be involved in human diseases came with the observation of parental UPD in Prader-Willi (PWS; Nicholls et al. 1989a) , Angelman (AS; Knoll et al. 1989) and Beckwith-Wiedeman (BWS; Henry et al. 1991) syndromes.
PWS and AS represent the most studied examples of imprinting in humans. Both syndromes are most commonly caused by deletions at 15q11-13, but the parental origin of the deletion differs, leading to very different phenotypes. PWS patients have hyperphagia, hypogonadism, mild mental retardation and behavioural defects (Butler 1990) , 50-60% of PWS patients have a cytogenetically visible deletion of paternal origin (Nicholls et al. 1989b) . AS patients are characterized by ataxia, severe mental retardation, seizures and a 'happy' disposition (Zori et al. 1992) ; in contrast to PWS, approximately 60% of AS patients inherit the deletion from their mother (Knoll et al. 1989) . For both diseases it was also discovered that they could be caused by UPD: maternal UPD in PWS (Nicholls et al. 1989a ) and paternal UPD in AS (Knoll et al. 1990 ). Thus, both deletion and UPD demonstrated that a maternal and paternal contribution were required at 15q11-13 for normal development, and suggested that oppositely imprinted genes were responsible for the two phenotypes. Evidence that different genes were responsible for these two syndromes came from the observation that in two three-generation families a 15q11-13 deletion caused AS when inherited maternally but not PWS when inherited paternally (Meijers-Heijboer et al. 1992 , Wagstaff et al. 1992 ; an AS candidate region mapping distal to PWS was subsequently identified (Buxton et al. 1994) .
Searches for transcripts from the PWS region identified five imprinted genes, all paternally expressed and therefore candidates for a role in the disease: SNRPN (O } zçelik et al. 1992), ZNF127 (Saitoh et al. 1996) , PAR1, PAR5 (Sutcliffe et al. 1994) and IPW (Wevrick et al. 1994) . A characteristic of imprinted genes, differential methylation (see Razin & Cedar 1994 for review), was also observed at a number of sites within the PWS/AS region (Dittrich et al. 1992 , Driscoll et al. 1992 , Glenn et al. 1993b ). In patients with biparental origin it was observed that these methylation patterns were disrupted in PWS and AS (Glenn et al. 1993a , Reis et al. 1994 , suggesting a disruption of the imprinting process over large regions.
Rare PWS and AS families with deletions of 5-60 kb, which result in loss of the 5 region of SNRPN, were shown to result in loss of imprinting of SNRPN, PAR1 and PAR5, and altered methylation patterns over 200 kb (Sutcliffe et al. 1994) . The fact that these deletions could disrupt the expression of paternally expressed genes when inherited from the father (resulting in PWS), but produced no phenotype when inherited maternally, strongly implicated this region in the control of imprinting at 15q11-13. Recently, a number of alternative transcripts of SNRPN have been identified, the most 5 exons of which map to a putative IC, and these are mutated in both PWS and AS families (Dittrich et al. 1996) . Analysis of three-generation families shows that the different lesions do not directly result in a lack of imprinted gene expression, but result in a failure to switch the epigenotypes in the germlines and thus affect imprinted expression over a 2 Mb chromosomal region. Interestingly, the mutations for PWS and AS map to two different positions within this region, indicating that this transcript performs separate functions required for the imprinting switch in male and female gametogenesis and thus the control of oppositely imprinted genes. Since SNRPN, and presumably the IC, is conserved in the mouse (Cattanach et al. 1992 , Leff et al. 1992 , experiments can now be carried out to try to dissect the mechanisms of the imprinting switch and the control of imprinted gene expression over large genomic regions.
Another well-studied human syndrome which displays imprinting effects is the BWS. BWS is a general overgrowth syndrome characterized by gigantism, macroglossia, visceromegaly and a number of other developmental anomalies (Elliott & Maher 1994) . In addition, individuals with BWS show a predisposition to embryonal tumours such as Wilms' tumour, rhabdomyosarcoma and hepatoblastoma (Junien 1992) . BWS maps to 11p15·5 and although most cases are sporadic and are karyotypically normal a small group of patients which show paternal UPD for this region suggested that the gene (or genes) involved may be imprinted (Henry et al. 1991) . Four imprinted genes have been mapped to 11p15·5 so far; the 
WT1
Embryonic lethal, failure of urogenital development Kreidberg et al. (1993) paternally expressed IGF2 and INS, and maternally expressed H19 and p57 KIP2 (see Table 1 for references). The paternal UPD cases of BWS would therefore suggest that this syndrome is caused by either overexpression of paternally expressed genes, or loss of maternal expression, or a combination of both. A number of lines of evidence suggest that IGF2 is a good candidate gene for BWS (Little et al. 1991) . Igf2 maps to mouse distal chromosome 7 (a region with homology of synteny to human 11p15·5) and the phenotype of mice with UPD of chromosome 7 shows growth defects (Ferguson-Smith et al. 1991) . IGF2 is known to function as a mitogen and targeted disruption of the Igf2 gene in the mouse produces a growth reduction phenotype (DeChiara et al. 1990) , and biallelic expression of IGF2 was observed in a number of BWS patients (Weksberg et al. 1993 , Reik et al. 1995 . However, the analysis of breakpoints in patients with balanced translocations suggests that the region involving BWS and related tumours is very large, around 5·5 Mb, and that BWS is therefore unlikely to be caused by a single locus (Hoovers et al. 1995) . In addition, patients with a biparental contribution at 11p15·5 were identified who have an altered pattern of allelic methylation within the region of H19 and IGF2, disrupting the normal imprinting of these genes, suggesting that an imprinting control centre may regulate the expression of a number of genes involved in BWS (Reik et al. 1995) . The study of families with small deletions, similar to those carried out on the PWS/AS families, will hopefully identify those sequences within the region which control the imprinting at 11p15·5.
Studies of other human overgrowth disorders which share characteristics of BWS have emphasized the role of IGF2 in embryonic growth control. Biallelic expression of IGF2 was observed in a patient with Wilms' tumour and gigantism (Ogawa et al. 1993a) . A non-syndromic overgrowth phenotype has been identified which shows biallelic IGF2 expression (Morison et al. 1996) , and mutations in a glypican gene (GPC3), which interacts with IGF2 and IGF2R, have been identified in Simpson-Golabi-Behmel syndrome (Pilia et al. 1996) .
Individuals with partial maternal UPD of human chromosome 7 have short stature and are growth retarded (Spotila et al. 1992) . A mouse imprinted gene (Peg1/Mest) has recently been identified on proximal chromosome 6, a region with homology of synteny with human chromosome 7, and thus represents a possible candidate for this disease (Kaneko-Ishino et al. 1995) . Another human syndrome with growth abnormality as part of the phenotype has been reported for maternal UPD of chromosome 14 (Healey et al. 1994) . Human chromosome 14 has homology of synteny with mouse chromosomes 12 and 14; UPD for both maternal and paternal mouse proximal chromosome 12 is embryonic lethal (Beechey & Cattanach 1996) . However, no imprinted genes have been mapped to this region.
Imprinted genes and cancer
A possible link between gametic imprinting and cancer was first identified in BWS. Patients with this syndrome have a predisposition to embryonal tumours such as Wilms' tumour, rhabdomyosarcoma and hepatoblastoma, and the demonstration of UPD for 11p15·5 indicated that imprinted genes may be involved in a syndrome which predisposes to cancer (Henry et al. 1991) .
Loss of imprinting (LOI) of a gene which is normally imprinted may be recognized if there is expression from both alleles. LOI of IGF2 and H19 in Wilms' tumours which did not show loss of heterozygosity (LOH) confirmed the initial observations in BWS patients (Ogawa et al. 1993b , Rainier et al. 1993 . Since this time, a number of studies have provided indirect evidence for the involvement of imprinted genes in cancer (Table 3) . It is possible to imagine two ways in which imprinted genes may result in cancer. LOH of an imprinted region, if it occurs on the chromosome from which the imprinted genes are expressed, could result in loss of a tumour-suppressor gene function. Alternatively, LOI may result in biallelic expression (overexpression) of a growth-promoting gene. Possible examples of both of these mechanisms are given in Table 3 , and others may be found in Feinberg (1993) .
Direct experimental evidence for the role which imprinted genes may play in tumorigenesis is so far limited. Transfection of tumour cells with an H19 expression construct indicated that H19 may have a tumoursuppressor function (Hao et al. 1993 , Moulton et al. 1994 , Steenman et al. 1994 . Mice with a targeted disruption of H19 are larger than wild-type, but this is attributed to the increase in expression of Igf2 (Leighton et al. 1995a) . Igf2, as may be suggested by the data in Table 3 , is a good candidate for involvement in tumour development. A mouse model system of oncogene-induced tumorigenesis in -cells (Christofori et al. 1994 (Christofori et al. , 1995 provides evidence for a role of Igf2 in tumorigenesis. It was shown that Igf2, which is not normally expressed in -cells, is expressed from both alleles in the -cell tumours. It remains to be determined if the mechanism of activation is the same for both the normally expressed paternal allele and the normally imprinted maternal allele, and if this is related to the mechanism of expression in those tissues which express Igf2 biallelically. The identification of factors which regulate gene expression in this and similar model systems should give an insight into the normal imprinting process and its disruption in cancer and disease.
It has been postulated that IGF2R functions as a tumour suppressor in liver and breast cancer, based on LOH and mutations identified on the remaining allele (De Souza et al. 1995a ,b, Hankins et al. 1996 . IGF2R disruption has also been observed by microsatellite instability in gastrointestinal tumours (Souza et al. 1996) . However, human IGF2R shows biallelic expression in the majority of tissues examined (Kalscheuer et al. 1993 , Ogawa et al. 1993c ).
However, the exact imprinting status of IGF2R remains unclear since a minority of individuals do show monoallelic expression in all tissues (Xu et al. 1993 ) and the human gene carries the same methylation imprint as the mouse gene (Smrzka et al. 1995 , Riesewijk et al. 1996 . Imprinting of IGF2R has been suggested to be polymorphic in humans, a similar polymorphism has also been reported for the Wilms' tumour gene (Jinno et al. 1994) . IGF2R functions as an antagonist of the mitogen IGF2 (Kornfeld 1992 , Ellis et al. 1996 and activates the growth inhibitor transforming growth factor-1 (Dennis & Rifkin 1991), and may therefore be considered a good candidate for a tumour-suppressor gene.
One imprinted gene which may be a good candidate for a role in tumour development is p57 KIP2 , a cyclindependent kinase (Cdk) inhibitor (Hatada & Mukai 1995) . Cdk inhibitors exert a negative regulatory effect on progression through the cell cycle, and p57 KIP2 can arrest cells in G1 (Lee et al. 1995 , Matsuoka et al. 1995 . Moreover, mice with a targeted disruption of a related Cdk inhibitor, p21 KIP1 show overgrowth and develop pituitary tumours (Fero et al. 1996 , Kiyokawa et al. 1996 , Nakayama et al. 1996 . Similar experiments for p57
KIP2
would be necessary to test this hypothesis, and would also be useful to probe the possible role of p57 KIP2 in BWS (Hatada et al. 1996) .
In humans, hereditary paragangliomas have an autosomal dominant mode of inheritance, but all affected individuals inherit the mutated allele from their father (Heutink et al. 1992 ). This evidence suggests that an imprinted, paternally expressed gene is mutated and responsible for the tumour phenotype in these patients. The gene has been mapped to chromosome 11q23-qter, but remains to be identified (Heutink et al. 1992) .
A large amount of data exists to show that allelic expression of some imprinted genes is changed in diverse tumour types (Table 3) . So far, these changes in imprinted gene expression have only been shown to correlate with the tumour phenotype. Since changes in imprinted gene expression most likely represent epigenetic changes, such as alterations in DNA methylation patterns, more detailed studies of imprinted gene expression in tumour pathology will increase our understanding of the contribution of non-genetic mutations to cancer causation. 
